ArticleEuropean radiology2019
FDG-PET/MRI in patients with pelvic recurrence of rectal cancer: first clinical experiences.
Article in European radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Pooled it
- FDG-PET/MRI in colorectal cancer care: an updated systematic review.Abdominal radiology (New York) · 2025Pooled it
- Diagnostic performance of [European journal of nuclear medicine and molecular imaging · 2022Pooled it
- [18F]FDG PET/MRI in rectal cancer.Annals of nuclear medicine · 2021Pooled it
- Rectal cancer: a methodological approach to matching PET/MRI to histopathology.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020Trial
- PET/MRI and PET/CT hybrid imaging of rectal cancer - description and initial observations from the RECTOPET (REctal Cancer trial on PET/MRI/CT) study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2019Trial
- Local recurrence in rectal cancer: from detection to structured reporting.Abdominal radiology (New York) · 2026Article
- Diagnostic Performance of [World journal of nuclear medicine · 2025Review
- Diagnostic and prognostic value of quantitativeAbdominal radiology (New York) · 2025Article
- Radiotherapy volume delineation based on MRI andAbdominal radiology (New York) · 2025Article
- Imaging in the era of risk-adapted treatment in colon cancer.The British journal of radiology · 2024Review
- [Treatment strategies for recurrent rectal cancer].Chirurgie (Heidelberg, Germany) · 2024Review
- PET/MRI in colorectal and anal cancers: an update.Abdominal radiology (New York) · 2023Review
- Rectal cancer pelvic recurrence: imaging patterns and key concepts to guide treatment planning.Abdominal radiology (New York) · 2023Review
- Surveillance strategies following curative resection and non-operative approach of rectal cancer: How and how long? Review of current recommendations.World journal of gastrointestinal surgery · 2023Review
- Rectal MRI Interpretation After Neoadjuvant Therapy.Journal of magnetic resonance imaging : JMRI · 2023Review
- Diagnostic performance ofAbdominal radiology (New York) · 2021Article
- Surgical treatment of locally recurrent rectal cancer: a narrative review.Annals of translational medicine · 2021Review
- Hybrid imaging of the abdomen and pelvis.Der Radiologe · 2020Review
- The added value of pelvic surveillance by MRI during postoperative follow-up of rectal cancer, with a focus on abbreviated MRI.European radiology · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine the value of
methodsForty-four patients (16 women, 28 men) with a history of rectal cancer who received FDG-PET/MRI between June 2011 and February 2017 at our institution were retrospectively enrolled. Three patients received two FDG-PET/MRIs; thus a total of 47 examinations were included. Pelvic recurrence was confirmed either with histology (n = 27) or imaging follow-up (n = 17) (> 4 months). Two readers (one radiologist, one nuclear medicine physician) interpreted the images in consensus. Pelvic lesions were assessed regarding FDG uptake and morphology. Sensitivity, specificity, positive and negative predictive values as well as accuracy of PET/MRI in detecting recurrence were determined.
resultsIn 47 FDG-PET/MRIs 30 suspicious pelvic lesions were identified, 29 of which were malignant. Two patients underwent resection and had histologically proven pelvic recurrence without showing suspicious findings on FDG-PET/MRI. Changes in management due to FDG-PET/MRI findings had been implemented in eight patients. Eighty per cent (16/20) of resected patients had histologically negative resection margins (R0), one patient had uncertain resection margins. Sensitivity of FDG-PET/MRI in detecting recurrence was 94%, specificity 94%, positive/negative predictive value and accuracy were 97%, 90% and 94%, respectively.
conclusionsFDG-PET/MRI is a valuable tool in the diagnosis and staging of pelvic recurrence in patients with rectal cancer. KEY POINTS: • Metabolic information obtained from PET coupled with excellent soft tissue contrast from MRI could facilitate detection of rectal cancer recurrence and assist in treatment planning. • PET/MRI demonstrates high sensitivity and specificity for the diagnosis of local recurrence of rectal cancer • PET/MRI led to alterations in management in 18.2% of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.